Literature DB >> 32479605

Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?

Aya Haggiagi1, Andrew B Lassman1.   

Abstract

Entities:  

Keywords:  MGMT; elderly; glioblastoma; methylation; radiotherapy; temozolomide

Mesh：

Substances：

Year:  2020        PMID： 32479605      PMCID： PMC7594572          DOI： 10.1093/neuonc/noaa136

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordan Xu; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2016-10-01       Impact factor: 12.300

2.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

3.  Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Authors:  James R Perry; Normand Laperriere; Christopher J O'Callaghan; Alba A Brandes; Johan Menten; Claire Phillips; Michael Fay; Ryo Nishikawa; J Gregory Cairncross; Wilson Roa; David Osoba; John P Rossiter; Arjun Sahgal; Hal Hirte; Florence Laigle-Donadey; Enrico Franceschi; Olivier Chinot; Vassilis Golfinopoulos; Laura Fariselli; Antje Wick; Loic Feuvret; Michael Back; Michael Tills; Chad Winch; Brigitta G Baumert; Wolfgang Wick; Keyue Ding; Warren P Mason
Journal:  N Engl J Med       Date:  2017-03-16       Impact factor: 91.245

4.  Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.

Authors:  Antje Wick; Tobias Kessler; Michael Platten; Christoph Meisner; Michael Bamberg; Ulrich Herrlinger; Jörg Felsberg; Astrid Weyerbrock; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Jan Vesper; Jürgen Debus; Jürgen Meixensberger; Ralf Ketter; Caroline Hertler; Regine Mayer-Steinacker; Sarah Weisang; Hanna Bölting; David Reuss; Guido Reifenberger; Felix Sahm; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

7.  Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Authors:  Wolfgang Wick; Christoph Meisner; Bettina Hentschel; Michael Platten; Alissa Schilling; Benedikt Wiestler; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Markus Weiler; Ghazaleh Tabatabai; Andreas von Deimling; Dorothee Gramatzki; Manfred Westphal; Gabriele Schackert; Markus Loeffler; Matthias Simon; Guido Reifenberger; Michael Weller
Journal:  Neurology       Date:  2013-09-25       Impact factor: 9.910

8.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316

9.  Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.

Authors:  Nimish A Mohile; Jaishri O Blakeley; Na Tosha N Gatson; Andreas F Hottinger; Andrew B Lassman; Douglas E Ney; Adriana Olar; David Schiff; Helen A Shih; Roy Strowd; Martin J van den Bent; Mateo Ziu
Journal:  Neuro Oncol       Date:  2020-04-11       Impact factor: 12.300
  9 in total
  1 in total

1.  Mutation-based clustering and classification analysis reveals distinctive age groups and age-related biomarkers for glioma.

Authors:  Claire Jean-Quartier; Fleur Jeanquartier; Aydin Ridvan; Matthias Kargl; Tica Mirza; Tobias Stangl; Robi Markaĉ; Mauro Jurada; Andreas Holzinger
Journal:  BMC Med Inform Decis Mak       Date:  2021-02-27       Impact factor: 2.796
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.